Published in Cancer Weekly, April 1st, 2008
PEG-SN38, a PEGylated form of SN38, utililizes new releasable PEGylation technology developed at Enzon. The technology enabled significantly increased solubility, a longer apparent half-life, higher exposure, and significantly enhanced therapeutic index compared to CPT-11 in several preclinical xenograft models, including models of in vivo CPT-11 resistance.
In an experiment using xenograft models for breast tumors, treatment with PEG-SN38 given below...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.